2011 Scrip 100: All aboard Teva's bullet train
This article was originally published in Scrip
Executive Summary
The global pharma industry is closely watching a company that has a stated aim of doubling its sales by 2015, aided by an ambitious branded product strategy and cash to spend on strategic acquisitions. This is how Teva will build its business in the post-Copaxone-protected era, CEO Shlomo Yanai tells Ashley Yeo.
You may also be interested in...
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024
Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.
German IVDs At The Turning Point: Digital And AI Show Future Market Direction
Europe’s largest national in vitro diagnostics market is evolving post-COVID, under the effects of new digital laws, artificial intelligence-enabled devices, apps on prescription and the rising popularity of continuous glucose monitors. The VDGH industry association’s latest survey indicates a changing market landscape for IVDs in 2024.